122.25
-2.84(-2.27%)
Currency In USD
| Previous Close | 125.09 |
| Open | 125.13 |
| Day High | 126.99 |
| Day Low | 122.05 |
| 52-Week High | 161 |
| 52-Week Low | 111.09 |
| Volume | 354,939 |
| Average Volume | 439,496 |
| Market Cap | 7.31B |
| PE | -15.75 |
| EPS | -7.76 |
| Moving Average 50 Days | 132.65 |
| Moving Average 200 Days | 133.02 |
| Change | -2.84 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $6,825.8 as of February 05, 2025 at a share price of $122.25. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $856.27 as of February 05, 2025 at a share price of $122.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2025 10:00 PM GMT
- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. A
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2025 1:30 PM GMT
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Easte
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
GlobeNewswire Inc.
Dec 19, 2024 1:30 PM GMT
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH